These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38902822)

  • 21. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.
    Liu M; Tseng TC; Jun DW; Yeh ML; Trinh H; Wong GLH; Chen CH; Peng CY; Kim SE; Oh H; Kwak MS; Cheung M; Toyoda H; Hsu YC; Jeong JY; Yoon EL; Ungtrakul T; Zhang J; Xie Q; Ahn SB; Enomoto M; Shim JJ; Cunningham C; Jeong SW; Cho YK; Ogawa E; Huang R; Lee DH; Takahashi H; Tsai PC; Huang CF; Dai CY; Tseng CH; Yasuda S; Kozuka R; Li J; Wong C; Wong CC; Zhao C; Hoang J; Eguchi Y; Wu C; Tanaka Y; Gane E; Tanwandee T; Cheung R; Yuen MF; Lee HS; Yu ML; Kao JH; Yang HI; Nguyen MH
    Hepatol Int; 2021 Feb; 15(1):71-81. PubMed ID: 33394321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea.
    Park YH; Kim BK; Kim JK; Kim HC; Kim DY; Park JY; Han KH; Kim SU; Shin SH; Hahn KY; Ahn SH
    J Gastroenterol Hepatol; 2014 May; 29(5):1005-11. PubMed ID: 24325579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF
    Semin Liver Dis; 2005; 25 Suppl 1():40-7. PubMed ID: 16103980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers.
    Kim HS; Baatarkhuu O; Lee HW; Park JY; Kim DY; Ahn SH; Song K; Han KH; Kim BK; Kim SU
    Liver Int; 2019 Jan; 39(1):81-89. PubMed ID: 30280461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of chronic hepatitis B in severe liver disease.
    Fung J; Lai CL; Yuen MF
    World J Gastroenterol; 2014 Nov; 20(43):16053-61. PubMed ID: 25473157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Prevalence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Infection in Thailand.
    Wanich N; Vilaichone RK; Chotivitayatarakorn P; Siramolpiwat S
    Asian Pac J Cancer Prev; 2016; 17(6):2857-60. PubMed ID: 27356702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gaps and Disparities in Chronic Hepatitis B Monitoring and Treatment in the United States, 2016-2019.
    Pham TTH; Toy M; Hutton D; Thompson W; Conners EE; Nelson NP; Salomon JA; So S
    Med Care; 2023 Apr; 61(4):247-253. PubMed ID: 36893410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.
    Liaw YF
    Antivir Ther; 2006; 11(6):669-79. PubMed ID: 17310811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural history of chronic hepatitis B: phases in a complex relationship.
    Croagh CM; Lubel JS
    World J Gastroenterol; 2014 Aug; 20(30):10395-404. PubMed ID: 25132755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Then and now: the progress in hepatitis B treatment over the past 20 years.
    Halegoua-De Marzio D; Hann HW
    World J Gastroenterol; 2014 Jan; 20(2):401-13. PubMed ID: 24574709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW; Kim SU; Park JY; Baatarkhuu O; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.
    Wong YJ; Nguyen VH; Yang HI; Li J; Le MH; Wu WJ; Han NX; Fong KY; Chen E; Wong C; Rui F; Xu X; Xue Q; Hu XY; Leow WQ; Goh GB; Cheung R; Wong G; Wong VW; Yu MW; Nguyen MH
    Clin Mol Hepatol; 2023 Jul; 29(3):705-720. PubMed ID: 37157776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
    Liang YJ; Teng W; Chen CL; Sun CP; Teng RD; Huang YH; Liang KH; Chen YW; Lin CC; Su CW; Tao MH; Wu JC
    Hepatology; 2021 Aug; 74(2):641-655. PubMed ID: 33675094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection.
    Liaw YF
    Nat Rev Gastroenterol Hepatol; 2019 Oct; 16(10):631-641. PubMed ID: 31477873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
    Xuan Hoan N; Thi Minh Huyen P; Dinh Tung B; Phuong Giang D; Tat Trung N; Tien Sy B; Thi Tuan N; Thi Ngoc Dung D; Reddy Pallerla S; Velavan TP; Hong Bang M; Huu Song L
    Gene; 2022 Jan; 806():145935. PubMed ID: 34478821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
    Lee HA; Lee HW; Kim IH; Park SY; Sinn DH; Yu JH; Seo YS; Um SH; Lee JI; Lee KS; Lee CH; Tak WY; Kweon YO; Kang W; Paik YH; Lee JW; Suh SJ; Jung YK; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yim HJ; Kim SU
    Aliment Pharmacol Ther; 2020 Jul; 52(1):196-204. PubMed ID: 32452564
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center.
    Vieira Barbosa J; Sahli R; Aubert V; Chaouch A; Moradpour D; Fraga M
    PLoS One; 2021; 16(4):e0250347. PubMed ID: 33905426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Choi WM; Kim GA; Choi J; Choi GH; Lee YB; Sinn DH; Lim YS
    Gut; 2024 Mar; 73(4):649-658. PubMed ID: 37813567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.